Best Stocks Under $2 to Watch in 2026

Before we get into tickers, it’s worth being blunt: stocks under $2 are speculative and can be extremely volatile. Prices can jump 30% in a day on hype and then give it all back just as fast. These are not “set it and forget it” retirement holdings; they’re more like high‑risk side bets.

A few things to know in this price range:

• You’ll see a lot of reverse splits (when companies shrink their share count to boost the price and stay listed on an exchange). That’s common on the NYSE and Nasdaq when a stock spends too long under $1.
• Dilution is a big risk. Many small companies regularly sell new shares or use “at‑the‑market” (ATM) offerings to raise cash, which can slowly push the price down even if the business is improving.
• Liquidity matters. Thinly traded names can move wildly on small orders. Always look at average daily volume before placing a trade.

For this list, we’re focusing only on U.S.-listed stocks on major exchanges, not OTC pink sheets. The companies below all have functioning businesses, recent news or catalysts, and enough trading volume that a retail investor can usually get in and out without too much drama. None of this is a buy or sell call—think of it as a research shortlist you can dig into on TradesZ and your broker’s tools.

If you’ve watched the electric vehicle boom from the sidelines, Arrival SA (ARVL) is one of those battered names trying to claw its way back while still trading under $2.

Arrival shifted its headquarters to the U.S. and now trades on Nasdaq after a brutal few years where its stock fell from double digits to well under a dollar, followed by a reverse split to keep its listing.^[1] The company is developing electric vans and buses, focusing on so‑called “microfactories” instead of giant auto plants.^[1]

Why it’s interesting in 2026:

• Low share price, high volatility: After its restructuring and reverse split, ARVL has been bouncing around under $2, with frequent double‑digit daily moves as traders react to funding headlines and production updates.^[1]
• Funding and survival are central questions: Arrival has repeatedly warned about its limited cash runway and need for additional capital.^[1] Any new funding agreement, large order, or strategic partner can move the stock sharply.
• Regulatory pressure is a tailwind: Commercial fleets are under pressure to cut emissions in the U.S. and Europe. If Arrival can actually ramp production and deliver vehicles at scale, revenue could inflect quickly—though that’s still a big “if”.^[1]

Key things to research further:

• Latest cash balance and burn rate from its most recent quarterly filing.
• Any new fleet orders or memorandums of understanding announced in 2025–2026.
• Details of any equity lines or ATM offerings that could dilute existing shareholders.

ARVL is a classic sub‑$2 “lottery ticket” on EV adoption: high potential reward if it survives and scales, very real risk of further dilution or even delisting if funding dries up.^[1]

Bird Global (BRDS), the shared e‑scooter company that was once a Silicon Valley darling, has spent much of 2025–2026 trading under $2 after a massive collapse from its SPAC days.^[2] The company operates scooter and bike fleets in cities around the world, charging riders per minute.

What’s going on now:

• In late 2023 and 2024, Bird exited some unprofitable markets, cut costs, and pursued restructuring to stay afloat.^[2]
• By 2025–2026, the stock has remained a low‑priced name, with the company still trying to prove it can be consistently profitable at the city level, not just on adjusted metrics.^[2]

Why some traders still watch BRDS under $2:

• Urban mobility is here to stay: Cities are still pushing for fewer cars and more micromobility options. Bird already has brand recognition and permits in key markets, which are hard for new entrants to obtain quickly.^[2]
• Every earnings report acts like a catalyst: When Bird reports quarterly results, traders zoom in on cash burn, city‑level profitability, and guidance on new partnerships or fleet upgrades. Any surprise in the numbers can spark a big move.
• Takeover/speculation angle: In a world where larger mobility or transportation platforms (think ride‑hailing or delivery companies) want to add scooters to their app, a beaten‑down name like Bird sometimes attracts buyout rumors when the valuation is tiny versus the footprint.^[2]

If you look into BRDS, focus on:

• The latest earnings call transcript and whether management is still guiding to positive free cash flow.
• Updates on city contracts, especially renewals or losses in major markets.
• The company’s debt and liabilities, given how capital‑intensive scooter fleets are.

BRDS sits squarely in “turnaround” territory—interesting for watchlists, but only if you’re comfortable with the possibility that equity holders may struggle if the balance sheet worsens.^[2]

Akebia Therapeutics (AKBA) is a small biotech focused on treatments for kidney disease. Its story has revolved around vadadustat, a pill aimed at treating anemia in chronic kidney disease patients.^[3]

Akebia climbed back onto many traders’ radars after a series of ups and downs with the U.S. Food and Drug Administration (FDA). In 2022–2023, the FDA initially rejected vadadustat, citing safety concerns.^[3] The company pursued an appeal and discussions continued into 2024 and beyond.^[3]

Why AKBA still matters under $2 in 2026:

• Regulatory catalysts: Any new FDA communication—label discussions, meeting minutes, or resubmission updates—can send the stock up or down sharply. Biotech names with a single core asset are especially sensitive to this.^[3]
• Ex‑U.S. revenue: Vadadustat is already approved in some territories outside the U.S. via partners, giving Akebia a revenue base to work with while it pushes for broader approvals.^[3]
• Balance between dilution and progress: Like many small biotechs, Akebia funds its research and commercialization efforts by issuing new shares or partnering. Under $2, traders closely watch each financing round and how it affects existing holders.^[3]

If you’re researching AKBA, pay attention to:

• The most recent 10‑Q/10‑K for cash runway and R&D spending.
• Any FDA meeting updates or press releases since late 2025—those are likely to be major drivers in 2026.
• Partner announcements around ex‑U.S. sales and any new indications being studied.

Biotech stocks like AKBA are binary in many ways: success with regulators and partners can re‑rate the stock; setbacks can be brutal. That’s why many retail traders keep positions small and treat them as speculative side bets rather than core holdings.^[3]

Plug Power (PLUG) used to be a multi‑billion‑dollar name in the hydrogen fuel cell space, but by early 2026 its share price has spent stretches flirting with the $2 line after a significant sell‑off in 2024–2025.^[4]

Plug sells hydrogen fuel cell systems and related infrastructure, pitching itself as a clean‑energy solution for forklifts, data centers, and heavy transport.^[4] The company has long touted a large "green hydrogen" buildout in North America and Europe.

Why PLUG shows up on sub‑$2 watchlists:

• Big revenue base for a low share price: Even after the sell‑off, Plug still reports hundreds of millions in annual revenue, which is rare for a stock trading this low.^[4]
• Balance sheet stress as a key plot point: In late 2023 and 2024, Plug raised red flags about its ability to continue as a going concern without more capital and better project economics.^[4] Markets have been watching every funding move and cost‑cut announcement since.
• Policy and subsidy tie‑in: Plug’s fortunes are tied to government incentives for hydrogen and clean energy. Changes in U.S. or EU policy, or delays in subsidy programs, can affect sentiment fast.^[4]

Things to dig into:

• Current gross margins and whether they’re trending closer to breakeven on key product lines.
• Updates on major hydrogen plant projects, including delays or cost overruns.
• Recent capital raises—convertible debt, equity offerings, or strategic investments that change the risk profile.

PLUG is not a tiny micro‑cap science project; it’s a real operating company whose stock has fallen far out of favor. That mix—large revenue but a penny‑stock price—makes it a magnet for traders who think sentiment might eventually turn if the balance sheet stabilizes.^[4]

The names above are just examples. New sub‑$2 opportunities pop up constantly as stocks fall from higher levels or reverse split to stay on the Nasdaq or NYSE. Instead of chasing every tip on social media, it helps to have a simple, repeatable process.

Here’s a straightforward way to build your own best stocks under $2 to watch in 2026 list:

• Screen for price and exchange: In your broker’s screener, filter for U.S. stocks listed on Nasdaq or NYSE, price between $0.50 and $2.00, and minimum average daily volume (for example, at least 500,000 shares).
• Check the business first, chart second: Open the latest 10‑Q or 10‑K. What does the company actually do? Is revenue growing, flat, or shrinking? A 50% price spike means little if the company has no clear path to making money.
• Look for a real catalyst: This might be an upcoming earnings date, a regulatory decision, a big contract renewal, or a product launch. Write down the date and what you expect the market to care about.
• Watch dilution risk: Search the filing for terms like “at‑the‑market offering,” “share issuance,” or “convertible notes.” If management has a habit of raising money every quarter, that’s a red flag for long‑term holders.
• Set your own rules: Many traders cap any single penny stock at a small percentage of their portfolio and decide in advance whether they’re trading around catalysts or holding longer term.

If you use TradesZ, you can combine this workflow with watchlists, news alerts, and simple valuation checks (like price‑to‑sales) to stay on top of changes without turning penny‑stock hunting into a full‑time job.